A phase III long-term study to evaluate the safety and efficacy of TAC-202 in patients with perennial or seasonal allergic rhinitis.
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Bilastine (Primary)
- Indications Perennial allergic rhinitis; Seasonal allergic rhinitis
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 07 Dec 2015 Status changed from active, no longer recruiting to completed.
- 13 Aug 2015 Status changed from recruiting to active, no longer recruiting.
- 21 Jan 2015 Status changed from not yet recruiting to recruiting.